Table 3.
Maximal inhibition of viral shedding (Imax) in response to UL29 siRNA treatment and sequence similarity with the UL29 siRNA swarm target.
| Strain | Imax, UL29 Swarm (%) 1 | Sequence Similarity (%) 2 | Differences per 100 Nucleotides 2 |
|---|---|---|---|
| HSV-1 (17+) | 99.85 | 100.0 | 0.00 |
| HSV-1 (F) | 99.79 | 99.85 | 0.15 |
| HSV-1 (Δ305) | 96.75 | 99.21 | 0.79 |
| F-14g | 97.34 | 99.85 | 0.15 |
| F-15 | 98.68 | 99.84 | 0.16 |
| F-17 | 97.95 | 99.70 | 0.31 |
| F-18g | 99.81 | 98.93 | 1.08 |
| F-19 | 99.22 | 99.85 | 0.15 |
| M-15 | 100.00 | 99.85 | 0.15 |
| M-10 | 100.00 | 99.85 | 0.15 |
| F-12 | 98.23 | 99.85 | 0.15 |
| F-15g | 100.00 | 99.85 | 0.15 |
| F-17/ | 99.78 | 99.85 | 0.15 |
| M-19 | 99.89 | 99.85 | 0.15 |
| M-17 | 100.00 | 99.85 | 0.15 |
| M-19/ | 98.69 | 100.0 | 0 |
| M-01 | 100.00 | 99.84 | 0.16 |
| M-02 | 99.81 | 99.69 | 0.31 |
| M-03 | 100.00 | 99.84 | 0.16 |
| M-04 | 100.00 | 99.85 | 0.15 |
1 Determined in Vero cells and expressed as reduction of viral production (%). The infection was done 4 h post treatment, using 100 plaque forming units/well of each virus. 2 In comparison to the UL29 siRNA swarm target: Nucleotides 59,954–59,302 according to the Genbank accession JN555585.1 [13]. An existing Genbank sequence was used for alignments when available.